(Total Views: 520)
Posted On: 04/25/2021 7:12:12 PM
Post# of 72444
(Coronavirus Today)
India-based Zydus Cadila announced that the company had received Restricted Emergency Use Approval from the Drug Controller General of India to use ‘Virafin,’ Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
The Phase III trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two-point statistically significant clinical improvement (WHO 7-point ORDINAL SCALE) on day 8 as compared to the Standard of Care (SOC arm) (80.36% vs. 68.18%).
https://www.coronavirustoday.com/2021/04/24/a...ents-india
There is a huge demand for anti-virals that is not going away. Go IPIX!
India-based Zydus Cadila announced that the company had received Restricted Emergency Use Approval from the Drug Controller General of India to use ‘Virafin,’ Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
The Phase III trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two-point statistically significant clinical improvement (WHO 7-point ORDINAL SCALE) on day 8 as compared to the Standard of Care (SOC arm) (80.36% vs. 68.18%).
https://www.coronavirustoday.com/2021/04/24/a...ents-india
There is a huge demand for anti-virals that is not going away. Go IPIX!
(2)
(0)
